Search results
Results from the WOW.Com Content Network
A drug combination targeting SARS-CoV-2, Paxlovid, was approved in December 2021 to treat COVID-19. [12] It is a combination of nirmatrelvir , a protease inhibitor targeted to the SARS-CoV-2 3C-like protease , and ritonavir, which inhibits the metabolism of nirmatrelvir, thereby prolonging its effect.
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources.
Guidelines, such as those provided by the Centers for Disease Control and Prevention (CDC) during the 2009 flu pandemic caused by the H1N1 virus, recommend, among other things, antiviral treatment regimens, clinical assessment algorithms for coordination of care, and antiviral chemoprophylaxis guidelines for exposed persons. [69]
In March 2022, the BBC wrote, "There are now many drugs that target the virus or our body in different ways: anti-inflammatory drugs that stop our immune system overreacting with deadly consequences, anti-viral drugs that make it harder for the coronavirus to replicate inside the body and antibody therapies that mimic our own immune system to ...
This conditional early approval system has previously been used in Japan to accelerate the progression to market of other antiviral drugs targeting COVID-19, including remdesivir and molnupiravir. [13] In a study of 428 patients, viral load was reduced, but symptoms were not significantly reduced. [14]
Antiviral drugs directly target the viruses responsible for influenza infections. Generally, anti-viral drugs work optimally when taken within a few days of the onset of symptoms. [ 3 ] Certain drugs are used prophylactically , that is they are used in uninfected individuals to guard against infection.
BSAs are potential candidates for treatment of emerging and re-emerging viruses, such as ebola, marburg, and SARS-CoV-2. [3] [4] Many BSAs show antiviral activity against other viruses than originally investigated (such as remdesivir and interferon alfa). Efforts in drug repurposing for SARS-CoV-2 is currently underway.